Search Results
Your search for ,Per matches 3906 pages
Showing 1101 - 1150Resurgence of COVID-19 Infection in a Large Highly Vaccinated U.S. Health System Workforce
In a letter to the editor in The New England Journal of Medicine, Jocelyn Keehner, MD, of the University of California San Diego Health (UCSDH), and colleagues describe a marked resurgence of COVID-19 infections among fully vaccinated workers in the UCSDH workforce in July 2021.1 The resurgence...
Factors Associated With Risk of Hearing Loss in Pediatric Patients Receiving Radiation and Chemotherapy
In a single-institution cohort study reported in the Journal of Clinical Oncology, Keilty et al identified factors associated with an increased risk of hearing loss in pediatric patients receiving radiation therapy and chemotherapy for central nervous system and head and neck tumors. The study...
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL
On October 1, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ZUMA-3 Efficacy was evaluated ...
Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening
Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...
Radioembolization Plus Second-Line Chemotherapy for Colorectal Liver Metastases
In the phase III EPOCH trial reported in the Journal of Clinical Oncology, Mary F. Mulcahy, MD, and colleagues found that the addition of transarterial yttrium-90 radioembolization (TARE) to second-line chemotherapy significantly prolonged progression-free survival and hepatic progression–free...
Adavosertib for Patients With TP53- and RAS-Mutant Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Seligmann et al, the phase II FOCUS4-C trial has shown activity of the WEE1 kinase inhibitor adavosertib in patients with TP53- and RAS-mutant metastatic colorectal cancer with disease control after first-line chemotherapy. As state by the...
Liver Biopsy for Evaluation of Hepatitis Associated With Immunotherapy
In a retrospective cohort study reported in a research letter in JAMA Oncology, Li et al found that the performance of liver biopsy in patients with grade ≥ 3 alanine aminotransferase (ALT) elevations during immune checkpoint inhibitor therapy was associated with a delayed start of corticosteroid...
Ga-68 PSMA-11 PET for Detection of Pelvic Nodal Metastasis in Intermediate- to High-Risk Prostate Cancer
In a collaborative phase III trial reported in JAMA Oncology, Thomas A. Hope, MD, and colleagues found that gallium-68 prostate-specific membrane antigen–11 positron-emission tomography (Ga-68 PSMA-11 PET) had 40% sensitivity and 95% specificity in the detection of pelvic nodal metastases prior to...
Overall Survival With the Bispecific Fusion Protein Tebentafusp for Metastatic Uveal Melanoma
In an interim analysis of the phase III IMCgp100-202 trial reported in The New England Journal of Medicine, Nathan et al found that tebentafusp, a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector, significantly improved overall survival vs...
Are Rates of Hepatocellular Carcinoma Rising in Rural Areas of the United States?
Historically, rates of hepatocellular carcinoma (HCC) have been lower in rural areas than urban regions. However, a recent study published by Zhou et al in Clinical Gastroenterology and Hepatology shows that while cases of HCC have begun slowing in urban communities in the United States, the...
Active Living After Cancer Program May Improve Physical Functioning for Breast Cancer Survivors
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, reported Tami-Maury et al in the journal Cancer. The results show the program could ...
Breathing Properly May Help You Live Longer
Every system in the body relies on oxygen. From cognition to digestion, effective breathing not only provides us with a greater sense of mental clarity, but it can also help us sleep better, digest food more efficiently, improve our body’s immune response, and reduce stress levels. According to...
Older Adults With Primary CNS Lymphoma: Treatment Opportunities and Challenges
The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Desai, and DeAngelis explore the treatment of older patients with primary central nervous system lymphoma (PCNSL), which pose...
Paradox Between Cost and Hematopoietic Cell Transplant Rate in Latin America
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Gregorio Jaimovich, MD, Director of the Bone Marrow Transplant Program at Favaloro University Hospital in Buenos Aires. Distinguished expert on radiation therapy and bone...
Study Examines Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The first randomized study in patients with malignant pheochromocytoma and paraganglioma has found that sunitinib prolongs progression-free survival by more than 5 months. The late-breaking results of the FIRSTMAPPP trial were presented by Eric Baudin, MD, PhD, and colleagues at the European...
Putting Radiotherapy to Best Use With CAR T-Cell Therapy in Lymphoma
The integration of radiation therapy into chimeric antigen receptor (CAR) T-cell therapy may improve outcomes for patients with relapsed or refractory lymphoma, according to Charles A. Enke, MD, Professor and the Bill Bures and Jerry Pabst Chair in Radiation Oncology at the Fred and Pamela Buffett...
First-Line Acalabrutinib, Venetoclax, and Obinutuzumab for Chronic Lymphocytic Leukemia
In a phase II study reported in The Lancet Oncology, Matthew S. Davids, MD, and colleagues found that first-line triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab produced measurable residual disease (MRD)-negative complete remission in a substantial proportion of patients ...
ATR Inhibitor Ceralasertib in ARID1A-Deficient and ARID1A-Intact Solid Tumors
In an ongoing phase II study, Aggarwal et al evaluated the efficacy of the ATR inhibitor ceralasertib alone and in combination with olaparib in patients with ARID1A-deficient and ARID1A-intact solid tumors. They observed antitumor activity with ceralasertib monotherapy in ARID1A-deficient solid...
Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better
In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter phase III ENGOT/GCIG trial. These results were presented during the 2021 ASCO Annual Meeting by Jacobus Pfisterer, MD, PhD, of the AGO Study Group and Gynecologic...
Study Shows Sentinel Lymph Node Biopsy to Be ‘Viable Option’ for Surgical Staging of Endometrial Cancer
Sentinel lymph node biopsy “had similar diagnostic accuracy and prognostic ability as lymphadenectomy in patients with high-grade endometrial cancer at greatest risk for nodal metastases,” according to the SENTOR trial, a prospective cohort study of 156 patients with clinical stage I disease. Using ...
With the Exception of Cervical Cancer, HPV-Associated Cancers Are on the Rise, Especially in Older Adults
Although the incidence of cervical cancer has decreased 1.03% a year over the past 17 years in the United States, likely due to screening or vaccination, other human papillomavirus (HPV)-associated cancers are increasing in both men and women, according to a study by Cheng-I Liao, MD, currently of...
Gynecologic Cancers 2020–2021 Almanac
The past year has been a remarkable and noteworthy time with much exciting progress made in gynecologic cancers, despite the underlying presence of the COVID-19 pandemic. Several key studies were presented in 2020–2021 that detailed the results of novel therapies for our patients with cervical,...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
CheckMate 648: First-Line Nivolumab Regimens Improve Survival in Esophageal Squamous Cell Carcinoma
As first-line treatment of advanced esophageal squamous cell carcinoma, nivolumab-containing regimens improved overall survival over standard-of-care chemotherapy, according to the first results of the global phase III CheckMate 648 trial presented at the 2021 ASCO Annual Meeting by Ian Chau, MD,...
FDA Grants Zanubrutinib Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
On September 15, zanubrutinib (Brukinsa), a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least...
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer
A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial presented at the 2021 ASCO Annual Meeting by investigators from China.1 In the study, toripalimab, an anti–PD-1 monoclonal antibody, ...
Cancer-Specific Urgent Care Center: Effect on Emergency Department Use and Hospitalization Rate
In a single-institution study reported in JCO Oncology Practice, Gould Rothberg et al found that establishment of a dedicated cancer urgent care center within a large tertiary academic center resulted in a significant but modest decrease in emergency department use—but no significant reduction in...
Technology-Enabled Monitoring of Adverse Reactions to Immune Checkpoint Inhibitors
In an interim analysis of a single-institution study reported in JAMA Network Open, Pavlos Msaouel, MD, PhD, and colleagues found that the use of a mobile device application for patient reporting of adverse reactions to immune checkpoint inhibition was feasible. It permitted identification of...
TITAN Confirms Survival Benefit of Apalutamide Plus ADT in Metastatic Prostate Cancer: Now, Move Therapy Forward
As reported in the Journal of Clinical Oncology by Chi et al1—and summarized in this issue of The ASCO Post—the prespecified final overall survival analysis of the phase III TITAN trial1-3 has confirmed a clear overall survival and radiographic progression-free survival benefit with the combination ...
Prevalence of Germline BRCA Mutations in Indian Women With Ovarian Cancer
Ovarian cancer is one of the most common gynecologic cancers, with 313,959 new cases and 207,252 deaths reported worldwide in 2020.1 Since there is no effective screening method, ovarian cancer in general is diagnosed in its late stage. The 5-year survival rate in women with ovarian cancer is less...
Maintained Benefit of Apalutamide Plus Androgen-Deprivation Therapy Shown in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the final overall survival analysis of the phase III TITAN trial showed significant benefit of apalutamide plus androgen-deprivation therapy vs placebo plus...
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in South Africa
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in South Africa. The aim of this special feature is to highlight the global cancer burden for various countries of...
IASLC 2021: Study Examines Global Risk of Lung Cancer Due to Air Pollution
Five European countries rank highest for lung cancer risk attributable to air pollution among those aged 50 to 69 years, according to research presented by Berg et al in the Presidential Symposium Plenary Session at the International Association for the Study of Lung Cancer (IASLC) 2021 World...
Study Finds Low-Poverty U.S. Counties May Eliminate Cervical Cancer 14 Years Earlier Than High-Poverty Counties
About 14,500 new cases of invasive cervical cancer are diagnosed each year in the United States and nearly 4,300 women die from the disease. Studies show that those living in higher-poverty areas experience higher rates of morbidity and mortality from many preventable cancers, including cervical...
Resurgence of COVID-19 Infection in a Large, Vaccinated Health System Workforce
In a letter to the editor in The New England Journal of Medicine, Keehner et al describe a marked resurgence of COVID-19 infections among fully vaccinated members of the University of California San Diego Health (UCSDH) workforce in July 2021. The resurgence appears to be driven by the confluence...
Assumptions, Data … and More Questions!
I read with great interest the results from the phase II ZUMA-12 study of axicabtagene ciloleucel, presented during the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 But the results raised several questions for me. Axicabtagene ciloleucel, an autologous anti-CD19...
HPV Vaccination and Projected Oropharyngeal Cancer Incidence Through the Year 2045
In a population-based age-period-cohort study reported in JAMA Oncology, Zhang et al estimated that current human papillomavirus (HPV) vaccination rates will have a limited impact on overall oropharyngeal cancer incidence through 2045, due to a high risk of oropharyngeal cancer in unvaccinated...
Liquid Biopsy Is Changing Colon Cancer Management
The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...
Report Aims to Assess Contemporary Burden of Brain Tumors in the United States
A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma
For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...
FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...
Study Examines Link Between Obesity in Long-Term Cancer Survivors and Increased Health-Care Utilization and Spending
A new study from the American Cancer Society published by Xuesong Han, PhD, and colleagues in the journal Cancer has found a link between obesity and the substantial economic burden of nearly $20 billion in 2016 among long-term cancer survivors in the United States, with one-third attributable to...
Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma
In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...
Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Prediction Models May Reduce False-Positives in Women With Dense Breasts Undergoing MRI Screening
Prediction models based on clinical characteristics and imaging findings may help reduce the false-positive rate in women with dense breasts who undergo supplemental breast cancer screening with magnetic resonance imaging (MRI), according to a study published by den Dekker et al in the journal...
Can Consumption of Vitamin D Reduce the Risk of Early-Onset Colorectal Cancer?
Consuming higher amounts of vitamin D—mainly from dietary sources—may help protect against developing young-onset colorectal cancer or precancerous colon polyps, according to the first study to show such an association. These findings were published by Kim et al in the journal Gastroenterology. The ...
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
In a phase I trial (MajesTEC-1) reported in The Lancet, Saad Z. Usmani, MD, FACP, and colleagues found that the B-cell maturation antigen (BCMA)-CD3 bispecific antibody teclistamab produced a high rate of durable responses at the recommended phase II dose in patients with relapsed or refractory...
